TIDMACPH 
 
 
   Acacia Pharma to present at the Upcoming Degroof Petercam Virtual 
Healthcare Conference 
 
   Cambridge, UK and Indianapolis, US -- 21 January 2021: Acacia Pharma 
Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a 
commercial stage biopharmaceutical company focused on developing and 
commercializing novel products to improve the care of patients 
undergoing serious medical treatments such as surgery, invasive 
procedures, or chemotherapy, announces that Mike Bolinder (CEO) and Gary 
Gemignani (CFO) will present a company overview to investors at Degroof 
Petercam's upcoming Virtual Healthcare Conference, which will take place 
on 26-29 January 2021. 
 
   Presentation slides will be made available after the event through the 
investor section of the Company's website, 
https://www.globenewswire.com/Tracker?data=Gz-aHKpJuwKXm7xJ9DH-yNExtvOy7nl4IkzxtZdZCEaqgkOe8wpTDUNn3ClzY_Pgo0J1DgZo-R0rhHaAPCWnKg70vF7L1Lwmycl-1hXdRdQ= 
www.acaciapharma.com. 
 
   ### 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                              Dible 
 +44 1223 919760 / +1 317 505 1280                Citigate Dewe Rogerson 
 mailto:IR@acaciapharma.com IR@acaciapharma.com   +44 20 7638 9571 
                                                  mailto:acaciapharma@citigatedewerogerson.com 
                                                  acaciapharma@citigatedewerogerson.com 
-----------------------------------------------  --------------------------------------------- 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    +32 499 58 55 31 
 +1 917-734-7387                                  mailto:chrisvanraemdonck@telenet.be 
 mailto:ikoffler@lifesciadvisors.com              chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
-----------------------------------------------  --------------------------------------------- 
 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
available in the US for the management of postoperative nausea & 
vomiting (PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved in the US for use during invasive 
medical procedures in adults lasting 30 minutes or less, such as 
colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK 
Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centred in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   www.acaciapharma.com 
 
   Forward looking statements 
 
   This announcement includes forward-looking statements, which are based 
on current expectations and projections about future events. These 
statements may include, without limitation, any statements preceded by, 
followed by or including words such as "believe", "expect", "intend", 
"may", "plan", "will", "should", "could" and other words and terms of 
similar meaning or the negative thereof. Forward-looking statements may 
and often do differ materially from actual results. These 
forward-looking statements are subject to risks, uncertainties and 
assumptions about the Company and its subsidiaries and investments, 
including, among other things, the development of its business, trends 
in its operating industry, and future capital expenditures and 
acquisitions. By their nature, forward-looking statements involve risk 
and uncertainty because they relate to future events and circumstances. 
Any forward-looking statements reflect the Company's current view with 
respect to future events and are subject to risks relating to future 
events and other risks, uncertainties and assumptions relating to the 
Group's business, results of operations, financial position, prospects, 
growth or strategies and the industry in which it operates. Save as 
required by law or applicable regulation, the Company and its affiliates 
expressly disclaim any obligation or undertaking to update, review or 
revise any forward-looking statement contained in this announcement 
whether as a result of new information, future developments or 
otherwise. Forward-looking statements speak only as of the date they are 
made.

(END) Dow Jones Newswires

January 21, 2021 07:00 ET (12:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Acacia Pharma Charts.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Acacia Pharma Charts.